The Headline That Doesn’t Make Sense Until It Does
Intuitive Surgical closed at $610.45 on January 22, 2025 — its all-time high. It closed at $402.30 on July 1, 2026 — a 34% decline from peak, including roughly 20% of that loss just since the start of 2026. That collapse happened while the company beat Q1 2026 estimates on revenue, earnings, and procedure volume, then raised its full-year guidance on the earnings call. Goldman Sachs reiterated a Buy rating and a $558 price target even after the drop — implying roughly 39% upside from here. Something in this picture is priced wrong.
Understanding ISRG right now means separating a genuinely strong quarter from a stock that’s been correcting from an expensive multiple for a year and a half.
What the Business Actually Did in Q1 2026
For the quarter ended March 31, 2026, Intuitive Surgical delivered results that beat Wall Street on every meaningful line:
1. Procedure volume — Worldwide procedures across the da Vinci and Ion platforms combined grew about 17% versus Q1 2025, with da Vinci procedures up roughly 16% and Ion procedures up about 39%. This is the number that matters most for a razor-and-blades medtech model: procedures drive the high-margin recurring instrument and accessory revenue, not just system sales.
2. System placements — The company placed 431 da Vinci systems in the quarter, up from 367 a year earlier, with the mix shifting decisively toward the newest da Vinci 5 platform (232 placements vs. 147 a year ago). It also placed 52 Ion systems. The installed base ended the quarter at 11,395 da Vinci systems (up 12% YoY) and 1,041 Ion systems (up 22% YoY).
3. Margins improved despite tariffs — Adjusted gross margin came in at 67.8%, up roughly 140 basis points year-over-year, even while absorbing tariff headwinds. Adjusted operating margin expanded nearly 480 basis points to 38.9%. This is a company getting more profitable per procedure, not less, even as trade policy works against it.
4. Capital return — ISRG repurchased 2.3 million shares for $1.1 billion during the quarter, drawing cash and investments down to $7.98 billion from $9.03 billion at the end of fiscal 2025 — management buying back stock through the decline.
Q1 2026 Numbers
| Metric | Result | YoY |
|---|---|---|
| Revenue | $2.77B | +23% |
| Adjusted EPS | $2.50 | +38.1% |
| Worldwide Procedure Growth | ~17% | Beat estimates |
| Adjusted Gross Margin | 67.8% | +140bps |
| Adjusted Operating Margin | 38.9% | +480bps |
| da Vinci Installed Base | 11,395 systems | +12% |
Why the Stock Fell 34% While the Business Kept Compounding
The disconnect breaks down into a few layers:
Layer 1 — It was priced at a premium multiple heading into 2025. ISRG has long traded at one of the richest valuations in medtech, reflecting its dominant, decades-long moat in robotic-assisted surgery. At $610, the stock was priced for flawless execution. Any deceleration — even a modest one — was going to compress that multiple hard.
Layer 2 — Tariff headwinds. Management has explicitly guided for an estimated tariff impact of about 1% of revenue on 2026 gross margin. That's a real, quantified cost pressure tied to trade policy, not a demand problem — but the market has been punishing any medtech name with tariff exposure regardless of how well the underlying business is absorbing it.
Layer 3 — Sector-wide medtech de-rating. ISRG's decline has tracked a broader premium-medtech selloff in 2026, not an ISRG-specific breakdown. The stock's ~29% six-month decline sits alongside similar pressure across the sector as investors rotate away from richly-valued healthcare names generally.
Layer 4 — A high bar to clear. When a stock has compounded as consistently as ISRG has over two decades, every quarter gets judged against an extremely high bar. A 17% procedure growth quarter that would be a career-defining result for most medtech companies reads as merely "in line" against ISRG's own history — and "in line" isn't enough to defend a premium multiple in a risk-off tape.
Where the Stock Stands Today
At $402.30, Intuitive Surgical carries a $145.4B market cap. The stock is down 34% from its January 22, 2025 closing high of $610.45, with roughly 20 percentage points of that decline occurring in 2026 alone. Despite the drawdown, Goldman Sachs maintained its Buy rating and $558 price target as recently as June 2026 — implying about 39% upside from current levels. Management raised its full-year 2026 da Vinci procedure growth outlook to 13.5–15.5% following the Q1 print, alongside guidance for adjusted gross margin of 67.5–68.5% (inclusive of the tariff drag) and adjusted operating expense growth of 11–14%.
Position Framework
- Starter: $390–$410 — near current price, reasonable entry given raised guidance and margin expansion
- Add: $360–$380 — if sector-wide medtech de-rating or a soft procedure print pushes it lower
- Trim: $520–$550 — as it approaches the Goldman target; re-evaluate at Q2 2026 earnings
- Target: $550–$600 over 12–18 months if procedure growth holds in the mid-teens and the tariff drag proves temporary
- Invalidation: Worldwide procedure growth decelerates meaningfully below 13%; da Vinci 5 adoption stalls; tariff impact widens materially beyond the guided ~1% of revenue
Intuitive Surgical just posted 23% revenue growth, 17% procedure growth, and expanding margins — then raised its own guidance — and the stock is still sitting a third below its all-time high. That's not a story about the business breaking down; it's a richly-valued compounder correcting from a multiple that priced in perfection, now working through tariff noise and a sector-wide medtech de-rating that has little to do with ISRG's actual execution. At $402, you're not paying for hype — you're paying for a company still growing procedures in the high teens with two decades of moat behind it.